Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
These changes arent just scale numbers
This implicitly includes maintaining records of which AI tool was used, the inputs/outputs, who reviewed them, what changes were made , and when they were authorized
GLP-1 medications do not directly cause hair loss
Cory Mellon, MD Last reviewed July 2026
convenience the core debate Foundayo enters the market just four months after Novo Nordisk launched oral Wegovy, highlighting contrasting competitive positions: Eli Lillys advantage: No fasting requirement, improving real-world adherence Novo Nordisks position: Clinical data shows ~14% weight loss, compared to 1011% for Foundayo No head-to-head trials have been conducted Pricing and access strategy To expand access amid high demand and limited insurance coverage: Cash-pay patients: ~$149/month (starter dose) Insured patients: Eli Lilly offers pricing as low as $25/month Commercial outlook Analysts expect Foundayo to become one of the most successful drugs in history: 2026 U.S
US$ 29.08
US$ 24.93
US$ 23.54
US$ 24.31
